Javascript must be enabled to continue!
FORMULATION AND EVALUATION OF METFORMIN HYDROCHLORIDE SUSTAINED-RELEASE ORAL MATRIX TABLETS
View through CrossRef
Objective: The aim of this investigation was to develop and optimize metformin hydrochloride matrix tablets for sustained release application. The sustained release matrix tablet of metformin hydrochloride was prepared by wet granulation technique using chitosan, xanthan gum, and hydroxypropyl methylcellulose at varying concentrations.Material and Methods: Extended release of metformin hydrochloride matrix tablets was prepared by wet granulation method. The influence of varying the polymer ratios was evaluated. The excipients used in this study did not alter physicochemical properties of the drug.Results: All the batches were evaluated for thickness, weight variation, hardness, and drug content uniformity. The in vitro drug dissolution study was carried out using USP apparatus Type II, paddle method, and the release mechanisms were explored. Mean dissolution time is used to characterize drug release rate from a dosage form and indicates the drug release is retarding efficiency of the polymer. This study revealed that as the concentration of matrix material increased, drug release from matrices decreased. This may be due to slower penetration of the dissolution medium into the matrices.Conclusion: Formulation with chitosan MS1 drug release was 86%, xanthan gum MS489%, and finally MS7 with hydroxypropyl methyl cellulose which exhibited the highest drug release retardation also had the lowest matrix concentration. Hence, lower concentration of polymers is suitable to prepare metformin hydrochloride tablets compared to higher concentrations.
Innovare Academic Sciences Pvt Ltd
Padmaja Bookya
Ramakrishna Raparla
Ramakrishna Raparla
Harikishan Prasad Sriramula
Ramakrishna Raparla
Sunitha Tarrigopula
Harikishan Prasad Sriramula
Sridhar Vanga
Ramakrishna Raparla
Harikishan Prasad Sriramula
Sunitha Tarrigopula
Harikishan Prasad Sriramula
Sridhar Vanga
Sunitha Tarrigopula
Sunitha Tarrigopula
Sridhar Vanga
Sridhar Vanga
Title: FORMULATION AND EVALUATION OF METFORMIN HYDROCHLORIDE SUSTAINED-RELEASE ORAL MATRIX TABLETS
Description:
Objective: The aim of this investigation was to develop and optimize metformin hydrochloride matrix tablets for sustained release application.
The sustained release matrix tablet of metformin hydrochloride was prepared by wet granulation technique using chitosan, xanthan gum, and hydroxypropyl methylcellulose at varying concentrations.
Material and Methods: Extended release of metformin hydrochloride matrix tablets was prepared by wet granulation method.
The influence of varying the polymer ratios was evaluated.
The excipients used in this study did not alter physicochemical properties of the drug.
Results: All the batches were evaluated for thickness, weight variation, hardness, and drug content uniformity.
The in vitro drug dissolution study was carried out using USP apparatus Type II, paddle method, and the release mechanisms were explored.
Mean dissolution time is used to characterize drug release rate from a dosage form and indicates the drug release is retarding efficiency of the polymer.
This study revealed that as the concentration of matrix material increased, drug release from matrices decreased.
This may be due to slower penetration of the dissolution medium into the matrices.
Conclusion: Formulation with chitosan MS1 drug release was 86%, xanthan gum MS489%, and finally MS7 with hydroxypropyl methyl cellulose which exhibited the highest drug release retardation also had the lowest matrix concentration.
Hence, lower concentration of polymers is suitable to prepare metformin hydrochloride tablets compared to higher concentrations.
Related Results
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract
BACKGROUND
Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer agent...
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract
Background: Metformin, an oral biguanide used for the treatment of type-2 diabetes mellitus (DM), has been shown in a considerable number of studies to have...
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract
Introduction and Objective. Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer age...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Morning exercise and pre-breakfast metformin interact to reduce glycaemia in people with Type 2 Diabetes: a randomized crossover trial
Morning exercise and pre-breakfast metformin interact to reduce glycaemia in people with Type 2 Diabetes: a randomized crossover trial
Abstract
Exercise is recommended in the treatment of Type 2 Diabetes and can improve insulin sensitivity [1]. However, previous evidence suggests that exercise at d...
Comparison of Total Hemispherical Reflectance and Emittance Values Between Metformin Extended-Release Tablets Stored Under Ambient and Stress Conditions
Comparison of Total Hemispherical Reflectance and Emittance Values Between Metformin Extended-Release Tablets Stored Under Ambient and Stress Conditions
Type 2 diabetes is a serious health problem worldwide. Metformin as the first-line drug in diabetes treatment mainly inhibits glucose production in the liver. Diabetes is often acc...
Design, Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Trazodone Hydrochloride
Design, Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Trazodone Hydrochloride
The present study aimed to develop and evaluate sustained -release matrix tablets of Trazodone Hydrochloride using a hydrophilic matrix system to achieve prolonged drug release and...
Vitamin B12 Status in Metformin Treated Diabetics: Cross Sectional Study
Vitamin B12 Status in Metformin Treated Diabetics: Cross Sectional Study
Background: Metformin is the most commonly used drug for patients with type 2 diabetes mellitus (T2DM) patients. Metformin related vitamin B12 deficiency can cause anemia. Accordin...

